Newmark Facilitates Sale of Cambridge Life Science Asset to King Street Properties

March 17, 2025 9:00 AM

Newmark announces it has facilitated the sale of 359 Allston Street, a life science property in Cambridge, Massachusetts. Newmark Co-Head of U.S. Capital Markets Robert Griffin, Executive Vice Chairman Edward Maher, Vice Chairman Matthew Pullen, Executive Managing Director James Tribble, Senior Managing Director Samantha Hallowell and Associate Director William Sleeper, in conjunction with Boston Private Capital Associate Directors Joseph Alvarado and Casey Valente, represented the undisclosed seller and procured the buyer, King Street Properties (“King Street”).

“359 Allston Street is occupied by a well-funded, fast-growing biotechnology tenant,” said Sleeper. “The asset is set on a quarter-acre lot with a highly efficient floor plate and exclusive outdoor spaces that make it an ideal Cambridge flagship for a tenant of this size.”

359 Allston Street was completely renovated in 2022. The 7,517-square-foot building is fully leased, serving as the headquarters of Vaxess Technologies. The property is situated minutes from Kendall Square, Cambridge’s renowned life science epicenter, as well as Massachusetts Institute of Technology, a top global research university. The property offers convenient transit connectivity, with an MBTA Red Line station located within a 12-minute walk.

“Acquiring 359 Allston Street was a strategic decision that aligns with our long-term vision and we appreciate Newmark’s assistance with the transaction,” said Tyson Reynoso, Managing Director/Partner at King Street Properties. “This building offers dynamic space for early-stage companies in East Cambridge, the premier life science location in the country.”

Newmark Financial Analyst Grady Zink provided support for the transaction.

About King Street Properties
King Street is a national firm with more than 20 years of experience specializing in life sciences properties in America’s core life science clusters including Boston/Cambridge, New York City, Raleigh/Durham, San Diego and the San Francisco Peninsula. The firm owns and operates 6.5 million square feet of real estate in major life science markets across the country.

About Newmark
Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries (“Newmark”), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark’s comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform’s global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the twelve months ended December 31, 2024, Newmark generated revenues of over $2.7 billion. As of December 31, 2024, Newmark and our business partners together operated from approximately 170 offices with more than 8,000 professionals across four continents. To learn more, visit nmrk.com or follow @newmark.

Discussion of Forward-Looking Statements about Newmark
Statements in this document regarding Newmark that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company’s business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark’s Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.